Truvelog Mix 30 (insulin aspart)
BiosimilarAdditional monitoring
- Region
- 🇪🇺 EU
- Active substance
- insulin aspart
- Company
- Sanofi Winthrop Industrie
- Status
- Withdrawn
- Therapeutic area
- Diabetes Mellitus
- CHMP opinion
- Thu 24 Feb 2022
- EU approval
- Mon 25 Apr 2022
- Designations
- Biosimilar, Additional monitoring
- Application
- EMEA/H/C/005635
- ATC
- A10AD05
- Official record
- www.ema.europa.eu
Indication
Truvelog Mix 30 is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 10 years and above.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Donrafylix Opinion · Kuraci
- 🇪🇺 Garzulys Opinion · Sciencepharma Sp. z o.o
- 🇪🇺 Dazparda Authorised · Sandoz GmbH
- 🇺🇸 Garzulys Approved · Emerge Bioscience Pte. Ltd.
- 🇪🇺 Insulin Aspart Injection Application withdrawn · Masuu Pharma Europe Limited
- 🇪🇺 Kirsty (previously Kixelle) Authorised · Biosimilar Collaborations Ireland Limited
- 🇪🇺 Insulin aspart Sanofi Authorised · Sanofi Winthrop Industrie
- 🇪🇺 NovoRapid Authorised · Novo Nordisk A/S
- 🇪🇺 Ryzodeg Authorised · Novo Nordisk A/S
- 🇪🇺 NovoMix Authorised · Novo Nordisk A/S
- 🇪🇺 Fiasp Authorised · Novo Nordisk A/S
Follow Truvelog Mix 30
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.